BRIEF published on 10/07/2024 at 13:05, 27 days ago Mises à jour de Theralase sur l'étude clinique sur le cancer de la vessie Approbation De La FDA Étude Clinique Theralase Cancer De La Vessie Ruvidar
BRIEF published on 10/07/2024 at 13:05, 27 days ago Theralase Updates on Bladder Cancer Clinical Study FDA Approval Clinical Study Theralase Bladder Cancer Ruvidar
PRESS RELEASE published on 10/07/2024 at 13:00, 27 days ago Theralase(R) Provides Update on Bladder Cancer Clinical Study Theralase® Technologies Inc. provides update on bladder cancer clinical study for BCG-Unresponsive NMIBC CIS using Ruvidar™ drug activated by TLC-3200 Medical Laser System, achieving positive interim results Clinical Study Theralase® Bladder Cancer RuvidarTM BCG-Unresponsive
BRIEF published on 09/24/2024 at 23:05, 1 month 8 days ago Theralase clôture un placement privé sans intermédiaire et émet des options sur actions Placement Privé Sans Intermédiaire Technologies Théralase Options Sur Actions Financement De La Recherche Clinique Étude Sur Le Cancer De La Vessie
BRIEF published on 09/24/2024 at 23:05, 1 month 8 days ago Theralase Closes Non-Brokered Private Placement and Issues Stock Options Stock Options Non-brokered Private Placement Theralase Technologies Clinical Research Funding Bladder Cancer Study
PRESS RELEASE published on 09/24/2024 at 23:00, 1 month 8 days ago Theralase(R) Closes Non-Brokered Private Placement and Issues Stock Options Theralase Technologies Inc. successfully closes Non-Brokered Private Placement offering of units for cancer research and development Private Placement Pharmaceutical Company Theralase Technologies Inc. Clinical Study Cancer Research
BRIEF published on 09/19/2024 at 23:10, 1 month 13 days ago Theralase® prolonge ses mandats Extension Bourse De Croissance TSX Technologies Théralase Bons De Souscription D'actions Développement Pharmaceutique
BRIEF published on 09/19/2024 at 23:10, 1 month 13 days ago Theralase® Extends Warrants Share Purchase Warrants TSXV Extension Theralase Technologies Pharmaceutical Development
PRESS RELEASE published on 09/19/2024 at 23:05, 1 month 13 days ago Theralase(R) Extends Warrants Theralase Technologies Inc. plans to extend expiry date of 10,000,000 share purchase warrants from Sept 22, 2024, to Sept 22, 2027. Warrants issued in 2022 at $0.35/share. TSXV approval pending TSX Venture Exchange Expiry Date Extension Theralase Technologies Inc. Share Purchase Warrants Clinical Stage Pharmaceutical Company
BRIEF published on 09/03/2024 at 13:05, 2 months ago Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus Theralase Ruvidar Antiviral Drug HSV-1 Acyclovir
Published on 11/03/2024 at 00:45, 12 hours 22 minutes ago Holtway Global Hedge Expands into Europe, Providing Exclusive Pre-IPO and IPO Access to Companies Led by Visionary Founders like Elon Musk and Sam Altman
Published on 11/02/2024 at 19:15, 17 hours 52 minutes ago Hank Payments Announces Closing of Financing and Settlements
Published on 11/02/2024 at 16:10, 20 hours 57 minutes ago Savencia Cheese USA Announces Voluntary Recall of Select Soft Ripened Cheeses
Published on 11/02/2024 at 14:30, 22 hours 37 minutes ago Spa Sciences Health Introduces Revolutionary Nasal Irrigation System at CVS
Published on 11/02/2024 at 00:48, 1 day 12 hours ago OneSoft Solutions Inc. Announces the Completion of Its Acquisition by Irth Solutions LLC, a Blackstone Portfolio Company
Published on 11/01/2024 at 21:31, 1 day 15 hours ago Original-Research: Telefonica Deutschland Holding AG (von First Berlin Equity Research GmbH): Buy
Published on 11/01/2024 at 18:18, 1 day 18 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/01/2024 at 17:47, 1 day 19 hours ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/01/2024 at 17:10, 1 day 19 hours ago EQS-Adhoc: fox e-mobility AG: provisional debt restructuring moratorium of Fox Automotive Switzerland AG
Published on 10/31/2024 at 18:19, 2 days 18 hours ago Déclaration hebdomadaire d'opérations effectuées du 28 au 31 octobre 2024
Published on 10/31/2024 at 18:19, 2 days 18 hours ago Disclosure of transactions in own shares on October 28 to October 31, 2024
Published on 10/31/2024 at 18:00, 2 days 19 hours ago GUILLEMOT CORPORATION : CHIFFRE D’AFFAIRES TROISIEME TRIMESTRE 2024 : +3%
Published on 10/31/2024 at 18:00, 2 days 19 hours ago GUILLEMOT CORPORATION: THIRD QUARTER 2024 TURNOVER UP 3%
